 The goal of this Phase II study is to identify if achieving full donor chimerism in whole blood, CD3, and leukemia-specific subset CD3, CD1415, CD19, CD33 and CD34 subset may decrease the risk of relapse of patients undergoing allogeneic transplant for hematologic malignancy. 